Evidence map›Paper›PMID 42734671›Full record

ReviewRadiologie (Heidelberg, Germany)2026

[Imaging diagnostics of kidney tumors : Scores and classification systems].

Andreas H Mahnken

Abstract readReviewEnglish Abstract
PubMed Publisher
In one paragraph

Review in Radiologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Andreas H MahnkenInstitut für Diagnostische und Interventionelle Radiologie und Nuklearmedizin, St. Josef-Hospital, Universitätsklinikum der Ruhr-Universität Bochum, Gudrunstraße 56, 44791, Bochum, Deutschland. andreas.mahnken@rub.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal cell carcinoma is one of the most common cancers and its mortality rate is falling due to continuous advances in diagnostics and treatment. Early detection using imaging techniques enables treatment with curative intent, resulting in a correspondingly favorable prognosis. Classification systems such as the TNM and Bosniak classifications as well as nephrometric scores, particularly the R.E.N.A.L. score, assist in prognosis assessment and support individualized treatment planning. They help to assess tumor complexity and the subsequent risk of postoperative or postinterventional complications; however, other anatomical and clinical factors, apart from nephrometric scores, must also be considered for an optimal individual treatment decision.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsHumansNeoplasm StagingPrognosisCross-sectional imaging techniquesNeoplasm stagingNephrometryRenal cell carcinomaTreatment planning

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.